Authors: | Kelly, W. K.; Slovin, S. F. |
Article Title: | Chemotherapy for androgen-independent prostate cancer: Myth or reality |
Abstract: | In the past, the treatment options for patients with metastatic prostate cancer that progressed despite castrate levels of testosterone was limited, and no therapies provided an improvement in survival. The majority of these patients had extensive osseous disease, multiple comorbidities, and poor performance status. With the widespread use of prostate-specific antigen (PSA) to monitor their clinical course, patients have presented with less extensive disease and a better performance status. Clinical trial methodology has improved as well, through incorporation of post-therapy changes in PSA to evaluate novel agents. This approach allows more patients to enter clinical trials, and the results show that the majority of these patients will have significant reduction in pain, regression of measurable disease, and suppression of PSA. These data suggest that prostate cancer is not as resistant to chemotherapy as it was once thought to be. |
Keywords: | androgen; clinical trial; review; antineoplastic agent; prostate specific antigen; antineoplastic combined chemotherapy protocols; tumor markers, biological; drug resistance; pathology; drug resistance, neoplasm; tumor marker; prostate-specific antigen; prostatic neoplasms; blood; prostate tumor; bioassay; antineoplastic agents, hormonal; antibiotics, antineoplastic; endpoint determination; antineoplastic antibiotic; testosterone; antineoplastic hormone agonists and antagonists; androgens; clinical trials; estramustine; humans; human; male |
Journal Title: | Current Oncology Reports |
Volume: | 2 |
Issue: | 5 |
ISSN: | 1523-3790 |
Publisher: | Springer |
Date Published: | 2000-10-01 |
Start Page: | 394 |
End Page: | 401 |
Language: | English |
PUBMED: | 11122870 |
PROVIDER: | scopus |
DOI: | 10.1007/s11912-000-0058-0 |
DOI/URL: | |
Notes: | Export Date: 18 November 2015 -- Source: Scopus |